Tech Company Financing Transactions
Jounce Therapeutics Funding Round
Casdin Capital, Cormorant Asset Management and Foresite Capital participated in a $56 million Series B funding round for Jounce Therapeutics. This venture round closed on 4/23/2015.
Transaction Overview
Company Name
Announced On
4/23/2015
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Jounce's pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. In addition, the investment will support expanded discovery of novel treatments aimed at tumors that may be less likely to respond to T cell checkpoint monotherapy, including therapies that target innate immune and stromal cells.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
780 Memorial Dr.
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Not Recorded
Overview
Jounce Therapeutics (NASDAQ: JNCE) is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Murray
Chief Financial Officer
Kim Drapkin
Chief Medical Officer
Elizabeth Trehu
Chief Technical Officer
Stephen Farrand
VP - Bus. Development
Hugh Cole
VP - Human Resources
Ted Harding
VP - Regulatory Affairs
Allison Nance
Browse more venture capital transactions:
Prev: 4/23/2015: Ariste Medical venture capital transaction
Next: 4/24/2015: Simplus venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs